NASDAQ:CNAT

Conatus Pharmaceuticals Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.

Add

Today's Range: $2.20
▼
$2.30
50-Day Range: $0.56
▼
$1.34
52-Week Range: $0.23
▼
$1.07

Volume: 58,264 shs
Average Volume: 1.28 million shs
Market Capitalization: $74.96 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Receive CNAT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Conatus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CNAT Stock Forecast (MarketRank)

Overall MarketRank^™

1.17 out of 5 stars

Medical Sector

1207th out of 1,432 stocks

Pharmaceutical Preparations Industry

594th out of 685 stocks

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Conatus Pharmaceuticals.

5.0 Community Rank

Outperform Votes
Conatus Pharmaceuticals has received 537 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Conatus Pharmaceuticals has received 137 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Conatus Pharmaceuticals has received 79.67% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Conatus Pharmaceuticals and other stocks. Vote “Outperform” if you believe CNAT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CNAT will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Conatus Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Conatus Pharmaceuticals does not have a long track record of dividend growth.

0.8 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Conatus Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
11.30% of the stock of Conatus Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 15.20% of the stock of Conatus Pharmaceuticals is held by institutions.

0.0 Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Conatus Pharmaceuticals is -7.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Conatus Pharmaceuticals is -7.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Conatus Pharmaceuticals has a P/B Ratio of 4.26. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Conatus Pharmaceuticals (NASDAQ:CNAT)

Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidate includes Emricasan, an orally active caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for portal hypertension; for liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function. The company is also developing CTS-2090, an orally active inhibitor of caspase 1, which is in preclinical development stage for treating chronic diseases involving inflammasome pathways. The company has a collaboration agreement with Novartis to conduct three Phase IIb clinical trials. Conatus Pharmaceuticals Inc. was founded in 2005 and is headquartered in San Diego, California.

September 6, 2020 | bloomberg.com

Conatus Pharmaceuticals' Emricasan Dosed in First Patient in Mayo Clinic Phase 2 Trial in Severe Alcoholic Hepatitis Population

August 22, 2020 | ca.finance.yahoo.com

CNAT Jan 2021 2.500 call

August 20, 2020 | ca.finance.yahoo.com

CNAT Oct 2020 2.500 call

August 1, 2020 | markets.businessinsider.com

News for Conatus Pharmaceuticals Inc

July 23, 2020 | www.bloomberg.com

Conatus Pharmaceuticals Announces Upcoming Oral Presentation at EASL Annual Meeting

May 27, 2020 | seekingalpha.com

Histogen completes tie-up with Conatus Pharma

May 18, 2020 | finance.yahoo.com

Leading Independent Proxy Advisory Firms Recommend Conatus Pharmaceuticals Shareholders Vote in Favor of its Merger with Histogen and the Required Reverse Stock Split

May 14, 2020 | finance.yahoo.com

Histogen Publishes Preclinical Data on its HST 004 Spinal Disc Program

May 11, 2020 | finance.yahoo.com

Histogen Receives US FDA IND Approval to Initiate Phase 1b/2a Trial of HST 001 in Androgenic Alopecia

May 7, 2020 | finance.yahoo.com

The Conatus Pharmaceuticals Special Meeting of Stockholders Seeking Approval for Proposed Merger with Histogen Inc. will Reconvene on May 21, 2020

May 1, 2020 | finance.yahoo.com

Conatus Pharmaceuticals Reports First Quarter 2020 Financial Results and Strategic Process Update

April 26, 2020 | www.fool.com

Conatus Pharmaceuticals

April 20, 2020 | finance.yahoo.com

Histogen Announces Investigational Device Exemption Application for HST 002

See More Headlines

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:CNAT
CUSIP: N/A
CIK: 1383701
Web: www.conatuspharma.com
Phone: 858-376-2600
Fax: N/A
Employees: 30
Year Founded: N/A

Company Calendar

Last Earnings: 5/01/2020
Today: 6/29/2022

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-11.39 million
Net Margins: -52.42%
Pretax Margin: N/A
Return on Equity: -48.22%
Return on Assets: -39.32%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 16.28
Quick Ratio: 16.28

Sales & Book Value

Annual Sales: $21.72 million
Price / Sales: 3.45
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.53 per share
Price / Book: 4.26

Miscellaneous

Outstanding Shares: 33,170,000
Free Float: N/A
Market Cap: $74.96 million
Optionable: Optionable
Beta: 1.84

Conatus Pharmaceuticals Frequently Asked Questions

How were Conatus Pharmaceuticals' earnings last quarter?: Conatus Pharmaceuticals Inc (NASDAQ:CNAT) issued its quarterly earnings results on Friday, May, 1st. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.10). Conatus Pharmaceuticals had a negative trailing twelve-month return on equity of 48.22% and a negative net margin of 52.42%.
View Conatus Pharmaceuticals' earnings history.
Who are Conatus Pharmaceuticals' key executives?: Conatus Pharmaceuticals' management team includes the following people:
Dr. Steven J. Mento, Co-Founder, Pres, CEO & Director (Age 67)
Dr. Keith W. Marshall MBA, Ph.D., Exec. VP, COO & CFO (Age 51)
Dr. David T. Hagerty, Exec. VP of Clinical Devel. (Age 64)
Dr. Alfred P. Spada, Co-Founder, Exec. VP of R&D and Chief Scientific Officer (Age 61)
Mr. Alan R. Engbring, Exec. Director of Investor Relations & Corp. Communications
Who are some of Conatus Pharmaceuticals' key competitors?: Some companies that are related to Conatus Pharmaceuticals include Ocular Therapeutix (OCUL), AC Immune (ACIU), CytoDyn (CYDY), Seres Therapeutics (MCRB), Biotech Acquisition (BIOT), Precigen (PGEN), Pliant Therapeutics (PLRX), Verona Pharma (VRNA), Aadi Bioscience (AADI), Alaunos Therapeutics (TCRT), Provention Bio (PRVB), Thorne HealthTech (THRN), Alpine Immune Sciences (ALPN), Prelude Therapeutics (PRLD) and InterCure (INCR).
View all of CNAT's competitors.
What other stocks do shareholders of Conatus Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Conatus Pharmaceuticals investors own include KNOT Offshore Partners (KNOP), Trevena (TRVN), PPL (PPL), (CASC) (CASC), Vaxart (VXRT), Antares Pharma (ATRS), Dextera Surgical (DXTR), Novavax (NVAX), Exelixis (EXEL) and Geron (GERN).

What is Conatus Pharmaceuticals' stock symbol?: Conatus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNAT."
What is Conatus Pharmaceuticals' stock price today?: One share of CNAT stock can currently be purchased for approximately $2.26.
How much money does Conatus Pharmaceuticals make?: Conatus Pharmaceuticals (NASDAQ:CNAT) has a market capitalization of $74.96 million and generates $21.72 million in revenue each year.
How many employees does Conatus Pharmaceuticals have?: Conatus Pharmaceuticals employs 30 workers across the globe.
How can I contact Conatus Pharmaceuticals?: Conatus Pharmaceuticals' mailing address is 16745 W. Bernardo Dr. Suite 250, San Diego CA, 92127. The official website for Conatus Pharmaceuticals is www.conatuspharma.com. The biotechnology company can be reached via phone at 858-376-2600 or via email at [email protected].

This page (NASDAQ:CNAT) was last updated on 6/29/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

MarketBeat Resources